期刊文献+

外周血sCTLA-4作为晚期非小细胞肺癌患者的预后因子 被引量:6

Peripheral blood sCTLA-4:prognostic factor of patients with advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:通过检测晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者外周血可溶性细胞毒性T淋巴细胞相关抗原4(soluble cytotoxic T lymphocyte associated antigen- 4,sCTLA-4)的表达,探讨其与晚期NSCLC患者生存期的关系。方法:采集2010年8月至2013年6月上海中医药大学附属龙华医院肿瘤科经病理证实的58例晚期NSCLC患者和30例正常人的外周血,运用ELISA法检测血中sCTLA-4含量,通过电话随访或上海市疾控中心获得患者生存期数据,分析sCTLA-4表达与NSCLC生存期的关系。结果:NSCLC患者外周血sCTLA-4表达率高于正常人(70.7% vs 6.7%, χ2=32.44,P〈0.01),外周血sCTLA-4增高的患者中位生存期(MST)较短(41.63个月vs 31.57个月, χ2=7.765,P〈0.01),死亡风险高于其他患者(RR=305, χ2=8.01, P〈0.01)。结论:NSCLC患者外周血中sCTLA-4高表达,sCTLA-4可能成为晚期NSCLC患者的预后因子之一。 Objective:To explore the relationship between soluble cytotoxic T lymphocyte associated antigen-4 (sCTLA-4) and the survival time of advanced NSCLC patients by examine its expressions in peripheral blood of patients. Methods: The research collected the peripheral blood of 58 advanced NSCLC patients confirmed by oncology department of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from August 2010 to June 2013, and also collected the peripheral blood from 30 healthy persons during the same time period. Researcher used ELISA to test the sCTLA-4 content in the blood, and obtained the data of survival time through telephone follow-up or collected from Shanghai Municipal Center for Disease Control and Prevention, to analyze the relationship between sCTLA-4 and survival time. Results: The sCTLA-4 in peripheral blood of NSCLC patients was higher than that of healthy people (70.7% vs 6.7%, χ2=32.44,P〈001); the median survival time of the patients with over-expressed sCTLA-4 was shorter (41.63 months vs 31. 57 months, χ2=7.77,P〈0.01) than those patients with low expression, indicating a higher death risk (RR=305, χ2=8.01, P〈0.01). Conclusion: sCTLA-4 was highly expressed in the peripheral blood of advanced NSCLC patients, and it could be used as one of the prognostic factors for patients with advanced NSCLC.
作者 吴立波 姜怡 姜维洁 李和根 许玲 田建辉 刘苓霜 WU Libo JIANG Yi JIANG Weijie LI Hegen XU Ling TIAN Jianhui LIU Lingshuang(Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, Chin)
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2016年第5期670-674,共5页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.81173224 No.81373621) 上海市科学技术委员会基金资助项目(No.13401905100) 上海中医药大学附属龙华医院"龙医团队"(D-11)~~
关键词 非小细胞肺癌 可溶性细胞毒T淋巴细胞相关抗原-4 免疫逃逸 预后因子 non-small-cell lung cancer soluble cytotoxic T lymphocyte associated antigen-4 (sCTLA-4) immune es-cape prognostic factor
  • 相关文献

参考文献1

二级参考文献32

  • 1Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
  • 2Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
  • 3Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical out-comes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol2003; 21: 1536-1543.
  • 4Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
  • 5Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8: 303-306.
  • 6Hirsch FR, Marileila VG, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with Gefitinib in a Phase III Placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
  • 7Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
  • 8The [IPASS] study. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009; 361: 947-957.
  • 9The ISTANA study. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010; 16: 1307-1314.
  • 10The WJTOG 3405 study. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol201O; 11: 121-128.

同被引文献71

引证文献6

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部